Special Issue

Advances in Colorectal Cancer: An Emerging Personalized Therapeutic Opportunity

Message from the Guest Editors

Colorectal cancer (CRC) is one of the most common malignant tumors worldwide. The cumulative findings of the past years demonstrate the existence of different pathways involved in CRC origin and progression. Due to the heterogeneity of CRC, surgery, chemotherapy, and radiation are ineffective in all cases. The integration of artificial intelligence algorithms into studies linking CRC to diagnosis and therapy will greatly enhance our understanding of the effects of individual-based cancer care. Furthermore, CRC treatment is entering a new era with robotic surgery and novel computer-assisted drug delivery techniques. This Special Issue aims to highlight the advantages and limitations of personalized medicine in CRC therapy. Studies include those that explore current scenarios of personalized medicine and the challenges faced in different countries. Finally, we encourage debates on the future perspectives of personalized medicine in CRC and how it could be integrated into the healthcare system.

Guest Editors

Dr. Alberto Vannelli

Department of Surgery, Valduce Hospital, Como, Italy

Dr. Tommaso A. Dragani

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Deadline for manuscript submissions

closed (16 December 2024)



Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/187405

Journal of Personalized Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). JPM is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

